LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Accueil・Liste d'Actions・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Fermé

SecteurSoins de santé

17.37 1.28

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

17.09

Max

17.49

Chiffres clés
By Trading Economics
Revenu	-607K -51M
Ventes	-28M 100M
BPA	-0.46
Marge bénéficiaire	-51.215
Employés	1,784
EBITDA	4.1M -44M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+88.92% upside

Dividendes
By Dow Jones
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-541M 1.8B
Ouverture précédente	16.09
Clôture précédente	17.37

Sentiment de l'Actualité

By Acuity

34%

66%

88 / 344 Classement par Healthcare

Zai Lab Ltd ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 juin 2026, 23:22 UTC

Résultats

Principaux Mouvements du Marché

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 juin 2026, 23:09 UTC

Actions en Tendance

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 juin 2026, 20:51 UTC

Résultats

Costco Reports 15% Sales Growth in May

3 juin 2026, 20:43 UTC

Résultats

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 juin 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 juin 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juin 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 juin 2026, 23:15 UTC

Market Talk

Résultats

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 juin 2026, 22:08 UTC

Actions en Tendance

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 juin 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 juin 2026, 21:18 UTC

Résultats

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 juin 2026, 21:15 UTC

Résultats

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 juin 2026, 21:13 UTC

Résultats

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 juin 2026, 21:13 UTC

Résultats

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 juin 2026, 21:12 UTC

Résultats

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 juin 2026, 21:09 UTC

Résultats

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 juin 2026, 21:03 UTC

Résultats

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 juin 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 juin 2026, 20:43 UTC

Résultats

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 juin 2026, 20:39 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 juin 2026, 20:37 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 juin 2026, 20:35 UTC

Résultats

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 juin 2026, 20:17 UTC

Résultats

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 juin 2026, 20:17 UTC

Résultats

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 juin 2026, 20:15 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q Adj EPS $2.44 >AVGO

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q EPS $1.91 >AVGO

3 juin 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q Rev $22.19B >AVGO

Comparaison

Variation de prix

Zai Lab Ltd ADR prévision

Objectif de Prix

By TipRanks

88.92% hausse

Prévisions sur 12 Mois

Moyen 32.4 USD 88.92%

Haut 44 USD

Bas 21.6 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

88 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.